<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468478</url>
  </required_header>
  <id_info>
    <org_study_id>HRHipertensao</org_study_id>
    <nct_id>NCT03468478</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation</brief_title>
  <acronym>SEM</acronym>
  <official_title>Comparison of the Efficacy and Safety of Sirolimus, Everolimus or Mycophenolate in Renal Transplant Recipients Receiving Induction With Anti-thymocyte Globulin, Tacrolimus and Prednisone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Rim e Hipertens達o</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital do Rim e Hipertens達o</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to compare 3 immunosuppression regimens: sirolimus and tacrolimus
      versus everolimus and tacrolimus versus mycophenolate and tacrolimus.

      The primary outcome is the incidence of cytomegalovirus infection / disease, a relevant
      medical need in the absence of pharmacological prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2017</start_date>
  <completion_date type="Anticipated">June 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of cytomegalovirus infection or disease</measure>
    <time_frame>12 months follow up</time_frame>
    <description>treatment of cytomegalovirus infection or disease within 12 months after kidney transplantation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Kidney Transplant Infection</condition>
  <arm_group>
    <arm_group_label>sirolimus +tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>everolimus +tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mycophenolate +tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>sirolimus combined to reduced dose of tacrolimus</description>
    <arm_group_label>sirolimus +tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>everolimus combined to reduced dose of tacrolimus</description>
    <arm_group_label>everolimus +tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic acid</intervention_name>
    <description>Control arm: mycophenolate combined to regular tacrolimus</description>
    <arm_group_label>mycophenolate +tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recipients, adults of the first living or deceased donor kidney transplant;

          2. Patients who agreed to participate in the study and signed the informed consent form

        Exclusion Criteria:

          1. Receptors with a medical history of nephrotic syndrome or focal and segmental
             glomerulosclerosis confirmed as the etiology of end-stage renal disease;

          2. Receptors with poor understanding about chronic kidney disease and its treatment
             alternatives;

          3. Receptors with early history of non compliance to treatment with immunosuppressive
             drugs;

          4. Retransplantation;

          5. Multi-organ recipients;

          6. Recipients with BMI&gt; 30 kg / m2;

          7. KDPI&gt; 80%;

          8. Cold ischemia time greater than 24 hours;

          9. Receptors with a percentage of anti-HLA antibodies above 50%, either class I or Class
             II;

         10. Women of childbearing potential who do not undertake contraceptive methods (condoms or
             oral contraceptives).

         11. Patients receiving immunosuppressive therapy prior to transplantation, except low dose
             of prednisone;

         12. Patients with severe uncontrolled dyslipidemia;

         13. Patients who have a known contraindication for administration of any of the
             immunosuppressive drugs provided for in this study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital do Rim</name>
      <address>
        <city>S達o Paulo</city>
        <state>Sao Paulo</state>
        <zip>04038002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Felipe', PharmD, PhD</last_name>
      <phone>551150878113</phone>
      <email>claudiafelipe@medfarm.com.br</email>
    </contact>
    <investigator>
      <last_name>Helio Tedesco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital do Rim e Hipertens達o</investigator_affiliation>
    <investigator_full_name>Helio Tedesco Silva Junior</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

